Back to Journals » Pharmacogenomics and Personalized Medicine » Volume 12

Personalized medicine in breast cancer: pharmacogenomics approaches

Authors Jeibouei S, Akbari ME, Kalbasi A, Aref AR, Ajoudanian M, Rezvani A, Zali H

Received 16 March 2018

Accepted for publication 27 March 2019

Published 27 May 2019 Volume 2019:12 Pages 59—73

DOI https://doi.org/10.2147/PGPM.S167886

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 4

Editor who approved publication: Dr Martin H. Bluth


Shabnam Jeibouei,1 Mohammad Esmael Akbari,2 Alireza Kalbasi,3 Amir Reza Aref,4,5 Mohammad Ajoudanian,6 Alireza Rezvani,7 Hakimeh Zali8

1Department of Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 2Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 3Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; 4Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA; 5Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; 6Department of Tissue Engineering and Applied Sciences, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 7Department of Hematology, Medical Oncology and Stem Cell Transplantation, Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; 8Proteomics Research Centre, Department of Tissue Engineering and Applied Sciences, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract: Breast cancer is the fifth cause of cancer death among women worldwide and represents a global health concern due to the lack of effective therapeutic regimens that could be applied to all disease groups. Nowadays, strategies based on pharmacogenomics constitute novel approaches that minimize toxicity while maximizing drug efficacy; this being of high importance in the oncology setting. Besides, genetic profiling of malignant tumors can lead to the development of targeted therapies to be included in effective drug regimens. Advances in molecular diagnostics have revealed that breast cancer is a multifaceted disease, characterized by inter-tumoral and intra-tumoral heterogeneity and, unlike the past, molecular classifications based on the expression of individual biomarkers have led to devising novel therapeutic strategies that improve patient survival. In this review, we report and discuss the molecular classification of breast cancer subtypes, the heterogeneity resource, and the advantages and disadvantages of current drug regimens with consideration of pharmacogenomics in response and resistance to treatment.

Keywords: breast cancer, personalized medicine, biomarker, pharmacogenomics


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]